| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8486721 | Vaccine | 2012 | 4 Pages |
Abstract
⺠We model the economic value of a QIV compared to the TIV for ten influenza seasons. ⺠QIV provided cost savings during the decade if used instead of the TIV. ⺠A higher costing (up to $120) vaccine would still be beneficial in some seasons. ⺠Adding an additional B strain could reap substantial savings.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Bruce Y. Lee, Sarah M. Bartsch, Alyssa M. Willig,